"Hemophilia A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Descriptor ID |
D006467
|
| MeSH Number(s) |
C15.378.100.100.500 C15.378.100.141.500 C15.378.463.500 C16.320.099.500
|
| Concept/Terms |
Hemophilia A- Hemophilia A
- Hemophilia As
- Hemophilia, Classic
- Hemophilia
- Hemophilia A, Congenital
- Congenital Hemophilia A
- Congenital Hemophilia As
- Hemophilia As, Congenital
- Classic Hemophilia
- Classic Hemophilias
- Hemophilias, Classic
- Haemophilia
Autosomal Hemophilia A- Autosomal Hemophilia A
- As, Autosomal Hemophilia
- Autosomal Hemophilia As
- Hemophilia A, Autosomal
- Hemophilia As, Autosomal
Factor VIII Deficiency- Factor VIII Deficiency
- Factor 8 Deficiency, Congenital
- Factor VIII Deficiency, Congenital
- Deficiency, Factor VIII
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia A".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia A".
This graph shows the total number of publications written about "Hemophilia A" by people in this website by year, and whether "Hemophilia A" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 1 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 4 | 1 | 5 |
| 2000 | 2 | 3 | 5 |
| 2001 | 5 | 0 | 5 |
| 2002 | 4 | 0 | 4 |
| 2003 | 6 | 2 | 8 |
| 2004 | 7 | 2 | 9 |
| 2005 | 9 | 2 | 11 |
| 2006 | 6 | 0 | 6 |
| 2007 | 10 | 2 | 12 |
| 2008 | 7 | 0 | 7 |
| 2009 | 5 | 2 | 7 |
| 2010 | 5 | 1 | 6 |
| 2011 | 11 | 4 | 15 |
| 2012 | 16 | 1 | 17 |
| 2013 | 12 | 1 | 13 |
| 2014 | 13 | 2 | 15 |
| 2015 | 8 | 0 | 8 |
| 2016 | 14 | 3 | 17 |
| 2017 | 11 | 0 | 11 |
| 2018 | 17 | 4 | 21 |
| 2019 | 15 | 2 | 17 |
| 2020 | 19 | 1 | 20 |
| 2021 | 23 | 2 | 25 |
| 2022 | 13 | 0 | 13 |
| 2023 | 19 | 0 | 19 |
| 2024 | 8 | 1 | 9 |
Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
-
Optimizing liver health before and after gene therapy for hemophilia A. Blood Adv. 2024 10 08; 8(19):5203-5212.
-
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs R D. 2024 Sep; 24(3):359-381.
-
Review of Inherited Coagulation Disorders. Anesth Prog. 2024 Jul 08; 71(2):87-95.
-
Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia. Blood Adv. 2024 06 11; 8(11):2707-2717.
-
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024 05 30; 143(22):2256-2269.
-
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII. Acta Haematol. 2025; 148(1):58-67.
-
Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives. Semin Thromb Hemost. 2025 Feb; 51(1):28-40.
-
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024 04 04; 143(14):1355-1364.
-
The benefits of gene therapy in people with haemophilia. J Viral Hepat. 2024 04; 31 Suppl 1:4-8.